Shattuck Labs, Inc. reported $1.0M of revenue over the trailing twelve months, −67% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.0M (to Q2 2026). Net income: −$53M, trailing twelve months to Q2 2026. EPS: −$0.47, trailing twelve months to Q2 2026.

STTKShattuck Labs, Inc.

Healthcare

$5.66+131% 1Y

$5.66

$1.7752 weeks$8.06

STTK as reported

Shattuck Labs, Inc. reported $1.0M of revenue over the trailing twelve months, −67% on the year before. 8 reported series are charted on this page, each one as filed.

$1.0M

Revenue, trailing twelve months · to Q2 2026 · −67% against the twelve months before

Net income: −$53M
Net income · −15% year on year · trailing twelve months to Q2 2026
EPS: −$0.47
EPS · −61% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for STTK, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.0M	−67%	Q2 2026
Net income	−$53M	−15%	Q2 2026
EPS	−$0.47	−61%	Q2 2026
Operating margin	−1619%	n/a	Q3 2024 · 7 quarters behind
Net margin	−1508%	n/a	Q3 2024 · 7 quarters behind
ROE	−49%	n/a	Q2 2026
ROA	−45%	n/a	Q2 2026
Free cash flow	−$61M	n/a	Q4 2024 · 6 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.